In addition, the methylations of RUNX3 and APC have been closely correlated with an increased risk of disease progression BE to EAC, whereas that of CDKN2A is related to dysplasia, having a potential role as a biomarker in early stages of dysplasia that may lead to progression from BE to EAC [161]. Here, RUNX3 is linked to dysplasia.